Continued strong sales increase and positive cash flow in third quarter

Q3 · Net sales reached SEK 28.3 (19.5) million. · Result after tax came in at SEK -1.9 (-7.7) million. · Earnings per share, basic and diluted, were SEK -0.01 (-0.05). · Cash and cash equivalents were SEK 33.7 (30.7) million. Significant events in Q3 · The results from Enzymatica’s in vitro study showed that ColdZyme® deactivates over 98% of the SARS-CoV-2 virus that causes COVID-19. At the end of the quarter the results of the study were reviewed, approved and published in the Journal of Medical Virology. · The results form Enzymatica’s placebo-controlled,